INT110817

Context Info Confidence 0.35 First Reported 2002 Last Reported 2008 Negated 0 Speculated 0 Reported most in Body Documents 3 Total Number 3 Disease Relevance 2.75 Pain Relevance 0.36

SCLC1 (Homo sapiens)

Pain Link Frequency Relevance Heat palliative 1 88.24 aspirin 50 76.44 cINOD 13 62.16 methotrexate 1 41.36 Inflammation 2 27.36 vincristine 8 5.00 Analgesic 3 5.00 Angina 1 5.00 alcohol 1 5.00 tolerance 1 5.00

Disease Link Frequency Relevance Heat Small Cell Lung Cancer 39 100.00 Toxicity 19 98.48 Disease 20 98.44 Non-small-cell Lung Cancer 7 98.00 Lung Cancer 36 96.48 Disease Progression 1 85.80 Death 1 80.84 Anaemia 6 77.60 Thrombocytopenia 10 76.56 Neutropenia 14 75.32

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Topotecan is a novel topoisomerase I inhibitor with established antitumor activity in recurrent SCLC and has a predictable, noncumulative toxicity profile.

Negative_regulation (inhibitor) of SCLC associated with toxicity and small cell lung cancer

1) Confidence 0.35 Published 2003 Journal Lung Cancer Section Abstract Doc Link 12781421 Disease Relevance 1.24 Pain Relevance 0.09

Our data are partly in contrast to these results, in that we observed the most marked reduction for SCLC, but also a significant decrease in risk for all NSCLC subtypes combined.

Negative_regulation (reduction) of SCLC associated with non-small-cell lung cancer and small cell lung cancer

2) Confidence 0.23 Published 2002 Journal BMC Cancer Section Body Doc Link PMC138809 Disease Relevance 0.58 Pain Relevance 0.28

Topotecan, a topoisomerase I inhibitor, is an active drug in relapsed SCLC.

Negative_regulation (inhibitor) of SCLC associated with small cell lung cancer

3) Confidence 0.13 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994215 Disease Relevance 0.93 Pain Relevance 0

General Comments

This test has worked.